Article

Bbarrons.com on 2020-01-24 15:22

BioMarin Stock Jumps as Analyst Calls Doubts Over Hemophilia Drug ‘Overblown’

RBC Capital Markets upgraded stock in the biotech firm BioMarin to Outperform.

Phase 2

Related news

BBioMarin Stock Jumps on Analyst Upgrade barrons.com
BBioMarin Slumps After FDA Rejects Its Hemophilia Gene Therapy barrons.com
Phase 1 , Wall Street
FDA blocks much-anticipated BioMarin hemophilia gene therapy Seattle Times
San Rafael
After surprise rejection of hemophilia gene therapy, BioMarin asks FDA to approve dwarfism drug bizjournals.com
A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last?bizjournals.com
BRegeneron Stock Jumps After Analyst Says Now Could Be a Good Time to Buy barrons.com
Coney Island
BBioMarin Stock Rises on Earnings Beat barrons.com
Europe
Hemophilia, The Musical? It’s Funded By Biotech BioMarin Forbes
Europe , Kentucky , Louisville , Utah , Cottonwood Heights
BioMarin delays refiling approval request for hemophilia gene therapy bizjournals.com
Why four years is important for BioMarin, hemophilia patients bizjournals.com
BBioMarin Drops After Hours on Weak Earnings barrons.com
Europe , Wall Street , Arén
BBioMarin’s Study of Its Hemophilia Gene-Therapy Looked Good barrons.com
BBristol Myers Stock Gets a Downgrade. Analyst Cites Doubts on Drug Pipeline.barrons.com
Bristol
Analyst: Coronavirus Derby threat is 'overblown'bizjournals.com
Hemophilia trial finds promising cure CNN
South America , Africa , Europe , New England
MFitbit competition from Apple overblown, analyst says marketwatch.com